Skip to content

Simethicone and N-acetylcysteine in Upper Endoscopy - Prospective Double-blinded Randomized Controlled Trial

Premedication With Simethicone and N-acetylcysteine in Improving Mucosal Visibility During Upper Endoscopy - a Prospective Double-blinded Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02357303
Enrollment
300
Registered
2015-02-06
Start date
2015-04-30
Completion date
2016-01-31
Last updated
2016-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Mucosal Lesion

Keywords

Randomized controlled trial, Endoscopy, Gastric mucosa, Simethicone, Acetylcysteine

Brief summary

The upper endoscopy is one of the most common methods for the diagnosis and treatment of upper gastrointestinal (GI) tract diseases and provides a unique opportunity to identify early neoplastic lesions. Before an upper endoscopy it is required a 6 hour fasting period\[1\]. However, even with this fasting period, sometimes the mucosal visualization, especially in the stomach, is impaired by the presence of foam, bubbles or gastric mucus. To improve visualization of the gastric mucosa, it is possible to administrate an oral solution of defoaming agents such as Simethicone and mucolytic agents like Pronase or N-Acetylcysteine previously to the procedure. The aim of this project is to determine if the use of premedication with simethicone, alone or in association with N-Acetylcysteine, improves mucosal visualization during an upper GI endoscopy.

Detailed description

a. Study type: prospective, randomized, double-blinded, placebo-controlled trial: i. Prospective inclusion of patients; ii. Randomization by computer generated tables; iii. Allocation concealment by sealed, opaque envelopes; iv. Double-blinded - nurse instructed not to reveal treatment; patient and doctor unaware of treatment; b. Patient selection: consecutive series of patients scheduled for upper gastrointestinal endoscopy; Exclusion criteria - sedation, previous total gastrectomy, known neoplasia or stenosis, allergies to simethicone or N-acetylcysteine, therapeutic or urgent procedures; c. Sample size: 270 (3 groups of 90 patients): to improve excellent preparations from 20% (value from our own database) to 40% and assuming a normal distribution and a power of 80% (α=0.05), the calculated sample size of each of the 3 groups was 82; allowing for a 10% dropout rate, the sample size is 90 (270 patients overall); Groups: Group A - 100mL of water (placebo); Group B - 100mL of water plus 100mg Simethicone; Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine; d. Data collection methods: form sheet filled by nurses (appendix 1) and endoscopist (appendix 2); e. Analysed variables: patients characteristics (age, gender), indication for endoscopy, time from administration to procedure, score of mucosal visualization, side effects of medication; f. Statistical analysis: chi-square test.

Interventions

100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy

DRUGAcetylcysteine

100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy

OTHERPlacebo

100mL of water

Sponsors

Portuguese Oncology Institute, Coimbra
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* consecutive series of patients scheduled for upper gastrointestinal endoscopy * signed informed consent

Exclusion criteria

* sedation * previous total gastrectomy * known neoplasia or stenosis * therapeutic or urgent procedures * allergies to simethicone or N-acetylcysteine

Design outcomes

Primary

MeasureTime frameDescription
Score of mucosal visualization1 day (During endoscopy)Evaluation of the visibility of gastric mucosa during upper endoscopy using a scale (excelent, adequadate or inadequate) for esophagus, stomach and duodenum

Other

MeasureTime frameDescription
Drug side effects1 day (During endoscopy)Evaluation of the drug side effects during upper endoscopy (report of any allergic reaction)

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026